

Remarks/Argument

By the present amendment, claim 1 has been amended, and claims 8-20, 24-28, and 35-36 have been withdrawn without prejudice or disclaimer. Support for amended claim 1 can be found at at least p. 8, ll. 5-7 and p. 12, ll. 12-15 of the present application.

In response to the Requirement for Restriction, Applicants hereby elect, with traverse, the invention of Group I and the species IGF-I, IGFBP3, and an absence of serum. It is respectfully submitted that claims 1-8 and 21-23 read on the elected invention.

Applicants respectfully traverse the restriction requirement regarding: (1) the citation of PCT Publication No. WO 02/24219 to Upton *et al.* (hereinafter, "Upton"); (2) the restriction of the claims to the single species of IGF-I or IGF-II; and (3) the restriction of the claims to the single species of IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5 or IGFBP6.

With regard to the citation of Upton, the Office Action argues that the inventions listed as Groups I-XIV do not relate to a single general inventive concept because Upton discloses a mammalian cell culture system comprising: (i) IGF-I and IGF-II; (ii) vitronectin; and an amount of serum for cell growth support. Claim 1 is directed to a cell culture medium comprising an absence or an amount of serum which in the absence of IGF-I or IGF-II would not support cell growth, whereas Upton is directed to a cell culture system comprising an amount of serum for cell growth support. Accordingly, Applicants respectfully submit that the present invention is generic with respect to IGF-I and IGF-II, IGFBP3 and IGFBP5, and an absence of

serum or an amount of serum which, in the absence of at least one IGF, would not support cell growth.

With regard to the restriction of the claims to IGF-I/IGF-II and IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5 or IGFBP6, Applicants respectively submit that IGF-I and IGF-II are both mitogenic peptide growth factors involved in cellular processes, while IGFBP3 and IGFBP5 are structural proteins that support the formation of a non-covalent protein complex between IGF-I and vitronectin. Accordingly, it would place no further burden on the Examiner to search and examine the present application with respect to IGF-II and IGFBP5.

An early action on the merits is respectfully requested.

Please charge any deficiency or credit any overpayment in the fees for this matter to our Deposit Account No. 20-0090.

Respectfully submitted,

/Richard S. Wesorick/

Richard S. Wesorick
Reg. No. 40,871

TAROLLI, SUNDHEIM, COVELL,
& TUMMINO L.L.P.
1300 East Ninth Street, Suite 1700
Cleveland, Ohio 44114
Phone: (216) 621-2234
Fax: (216) 621-4072
Customer No.: 26,294